Peripheral Blood Cells from Patients with Hodgkin’s and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs

Table 1

Patient characteristics.

	COHORT 1		COHORT 2
	DLBCL,	HL,	DLBCL,	HL,
Male	14 (67%)	5 (25%)	2 (17%)	5 (24%)
Age, median (range)	61 (24–82)	33 (19–68)	65 (39–82)	31 (23–68)
CS III/IV	13 (62%)	7 (35%)	15 (88%)	7 (33%)
B symptoms	10 (48%)	7 (35%)	8 (47%)	11 (52%)
Extranodal involvement	15 (71%)	5 (25%)	9 (52%)	4 (19%)
Bulky disease (more than 5 cm)	7 (33%)	9 (45%)	5 (25%)	10 (47%)

DLBCL: diffuse B cell large lymphoma; HL: Hodgkin lymphoma; CS: clinical status according to the Ann Arbor staging system. Data are expressed as number (percentage) or as the median (range). 18 HL/17 DLBCL and eight HL/nine DLBCL patients, respectively, after treatment.